Fake News and Competitive Strategy

Posted by Malini Solanki

Jan 3, 2017 1:54:02 PM

The diagnostic industry provides essential information for healthcare, and is driven by medical technology, the aging population, and the complexity of disease. One sector, the global blood testing market, in 2015 was valued at $51.5 billion and is expected to grow to $62.9 billion by 2024. Understanding how to craft strategy in this market is critical, given the funding required for new ventures, and it is nuanced, given the often unusual business practices that can be employed by one's competitors. 

Read More

Topics: Competitive Intelligence, Pharma, Competitive Strategy

Upcoming Event: Robert Flynn Speaking at Pharma CI US Conference & Exhibition September 14th

Posted by Fuld + Company

Aug 23, 2016 9:19:47 AM

Join us this month at the Pharma CI Conference & Exhibition taking place September 13th - 14th at the Hilton Parsippany in Parsippany, New Jersey.

The Pharma CI Conference & Exhibition is the largest assembly of senior level pharmaceutical, biotech, and medical device professionals seeking the latest news and the chance to network with all the industry’s luminaries.

Members of our Life Sciences team will be at our booth to find out how we can address your competitive intelligence and strategy development needs in the pharmaceutical, biotech, medical device, and diagnostics industries. Robert Flynn, Principal, Strategic Accounts, will be giving a talk on early warning through scenario planning on Wednesday, September 14th.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Fuld + Company, Pharma, Scenario Analysis

Medication-Induced Syndromes Offer Growth Opportunity

Posted by Kyle Nicholson

Aug 15, 2016 1:40:17 PM

Opioid-induced constipation, tardive dyskinesia, and other medication-induced syndromes present worthwhile revenue opportunities for pharmaceutical R&D.

In the 1960s, researchers discovered that the loss of motor control from Parkinson’s disease (PD) was tied to a deficiency of dopamine in a part of the brain involved in the coordination of movement.

Evidence soon established that administration of levodopa, a dopamine precursor molecule, dramatically improved PD symptoms. Here’s the catch: relief of symptoms was accompanied by severe nausea and vomiting. Levodopa was not only being converted to dopamine in the brain but also in the bloodstream, activating dopamine receptors in the peripheral nervous system and causing the adverse side effects.

Read More

Topics: Pharma, Life Sciences, Product Positioning, Competitive Strategy

Teva Membership in PhRMA Benefits Brand-Name Pharma

Posted by Steve Ames

Jul 12, 2016 10:53:02 AM

Teva, the world’s largest producer of generic medications, recently requested membership into Pharmaceutical Research and Manufacturers of America (PhRMA), the powerful US trade association of brand-name medicine manufacturers.

PhRMA is a lobby powerhouse, largely due to representation from most of the biggest players in the pharmaceutical industry. As detailed in the New York Times, Teva’s request ruffled the feathers of some PhRMA members who see Teva (and other generics companies) as a threat to the success of branded medicine. Brand-name and generic drug companies are no strangers to court battles against each other, typically around brand patent validity and timelines for generic entrance.

Read More

Topics: Innovation, Pharma, Life Sciences, Competitive Strategy

Defending Market Share in Pharma

Posted by Fuld + Company

Mar 18, 2016 9:49:49 AM

Pharmaceutical firms frequently need to defend their market position against rivals’ competitive strategy. Threats to leading therapies can come in many forms:

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Cycle Management, Life Sciences, Competitive Strategy

Filgotinib: Still Early to Pop the Champagne

Posted by Adi Reske

Dec 24, 2015 12:38:39 PM

Recently, Galapagos NV and Gilead entered a partnership, potentially worth more than $2 billion, to develop Galapagos’s oral JAK1 inhibitor, filgotinib, for inflammatory diseases.

Earlier in December 2015, Galapagos announced positive interim Phase II Crohn’s disease results for filgotinib. Based on the data presented, 48% of moderate to severe CD patient treated with filgotinib achieved clinical remission at 10 weeks compared to 23% placebo (p=0.0067); clinical response (CDAI decrease of 100 points or more) as well improvement in patients’ quality of life were also met in the study. According to the company’s CEO, results from the Phase II trial merit moving the drug into a Phase III Crohn's program “as soon as possible”.

Read More

Topics: Brand Insights, Pharma, Life Sciences, Product Positioning

New Video! Building a Life Sciences CI Team

Posted by Fuld + Company

Dec 15, 2015 9:50:08 AM

Finding the right talent to fill CI needs at a Life Sciences company can be challenging. From companion diagnostics to biosimilars, it's a complex marketplace that requires highly skilled CI practitioners.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss necessary industry experience and academic qualifications for inclusion in a CI team, as well as team dynamics within Fuld + Company's own Life Sciences practice.

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Sciences

New Video! Companion Diagnostics

Posted by Fuld + Company

Dec 11, 2015 8:00:00 AM

Companion diagnostic (CDx) devices are in vitro and imaging tools that are paired with specific drug therapies. Part of a larger trend towards personalized medicine, they are used to identify patients most likely to benefit from a specific therapeutic agent or to determine appropriate dosage. 

While questions remain about who should bear the cost for companion diagnostics, the promise of greater safety and efficacy and the potential for faster regulatory approval have made this an area of growth for both pharmaceutical and molecular diagnostics clients.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss increased requests for monitoring development and expansion of CDx platforms, earlier coordination by pharmaceutical and diagnostics firms, and the benefits of CI for optimizing R&D spending.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Medical Devices, Pharma, Healthcare, Life Sciences

Pfizer’s Xeljanz: An Uphill Battle

Posted by Adi Reske

Oct 28, 2015 9:32:16 AM

Approx. 6 million people in the US have plaque psoriasisOn October 14th, 2015, Pfizer announced receipt of a Complete Response Letter (CRL) from the FDA regarding its recent supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib) in moderate to severe plaque psoriasis.

The FDA accepted Pfizer’s filing in February 2015 based on data from the Phase III Oral treatment Psoriasis Trials (OPT) Program. A global, multi-study, clinical development program, OPT was designed to evaluate Xeljanz 5 mg and 10 mg twice daily in patients with the skin disorder.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Life Sciences, Competitive Strategy

Jack Bauer and the Flu

Posted by Robert Flynn

Oct 23, 2015 6:49:12 AM

On February 5, 2015, Public Health England announced that the flu vaccine had demonstrated low effectiveness against the main strain of flu that had circulated this past winter. Dr. Michael Skinner of Imperial College London, said in response, “Trying to predict which seasonal flu vaccine to produce each year must be a bit like a Jack Bauer car chase in Los Angeles…bound to prove somewhat hit & miss.” 

A similar miss occurred in 2004, when the United States suspended The Chiron Corporation’s shipment of 48 million doses of vaccine, citing problems at the company’s Liverpool, England, manufacturing plant.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Scenario Analysis, Healthcare, Life Sciences, Merger and Acquisition

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.